Additionally, a small randomizedcontrolled trial in patients with heart failure and reduced ejection fraction(HFrEF) found that sodium–glucose cotransporter 2 inhibitors (SGLT2-i), incombination with other heart failure therapies, improved RV function moreeffectively than standard treatments alone [39]. This evidence concerns the gene SLC5A2 and heart failure.